Neuphoria Therapeutics Inc (NEUP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.77+0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NEUP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers
NEUP — M&A activity — Changes in Control of Registrant
Dated 2026-07-24
Changes in Control of Registrant. To the extent required by this Item, the information included in
Why it matters: Health Care sector growth trends impact Neuphoria's potential for revenue growth.
Watch forSector revenue growth is speeding up again. This shows a positive change.
Also watch forSector revenue growth is slowing down. This shows ongoing problems.
Why it matters: New data could show that iSCIB1+ works well. Good results may attract investors and help the merger.
Supportive ifMore data will come from the Phase 2 SCOPE study. It will show Progression Free Survival and Overall Survival in the next 12 months.
Worry ifData release shows poor results. This raises concerns about how well iSCIB1+ works.
Why it matters: If management changes how they use capital, it may help growth. Right now, they are not friendly to capital.
Supportive ifManagement has a new plan. They want to invest more money in R&D.
Worry ifManagement still has a capital unfriendly approach. They have not made new investments.
Why it matters: Approval will let Neuphoria trade on a big exchange. This will raise visibility and interest.
Supportive ifNasdaq will approve the listing for the combined company by late Q4 2026.
Worry ifNasdaq denied the listing application. This stops the merger from being completed.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$130 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $746 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,350 loss on $10,000 · 83.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The earnings date will provide insight into financial performance and future plans.
Watch forThe next earnings date is announced. This shows a commitment to being open.
Also watch forNo earnings date is announced. This suggests uncertainty or problems.
Why it matters: If revenue growth falls below its median, it signals a slowdown in the sector. This could impact Neuphoria's performance as it is currently losing money.
Worry ifSector revenue growth has been below its historical median for two quarters.
Less concerning ifSector revenue growth is still above its historical median.
Why it matters: Approval is needed to complete the merger. This merger will affect future growth and funding.
Supportive ifNeuphoria and Scancell shareholders agree to merge at their meetings.
Worry ifOne company does not get the needed shareholder approval for the merger.
Why it matters: Financing is needed to support the Phase 3 trial of iSCIB1+. This trial is key for future growth.
Supportive ifNeuphoria secures at least $75 million in financing by late Q4 2026.
Worry ifFinancing falls short of the $75 million target, impacting trial plans.
Why it matters: If health care revenue growth speeds up, it could boost Neuphoria's outlook. Investors look for signs of sector strength.
Supportive ifHealth care revenue growth accelerates back toward 10% or higher year over year.
Worry ifHealth care revenue growth continues to decelerate below 10% year over year.
Why it matters: Securing financing is crucial for the Phase 3 trial of iSCIB1+. It impacts cash runway and future development.
Supportive ifThe company will raise $79.1 million through planned financing. This will happen before the merger is complete.
Worry ifThe company fails to raise the targeted $79.1 million, impacting the Phase 3 trial timeline.